Evaluation of soluble glycoprotein V as an <i>in vitro</i> quality marker for platelet concentrates: a correlation study between <i>in vitro</i> platelet quality markers and the effect of storage medium

Kiminkinen, L. K. Marjatta; Krusius, Tom; Javela, Kaija

doi:10.1111/vox.12402

Cited by 7 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, different molecular indicators are employed in the determination of platelet activation (34). Since EVs are produced as a result of cell activation (55), they have also been suggested to serve as a measure of platelet activation (35,36,56).…”

Section: Discussionmentioning

confidence: 99%

“…When activated, platelets produce EVs with an activation-dependent composition (32,33). During storage, the platelet activation state as well as the concentration of EVs increase in the PLC (34)(35)(36), which may have an impact on the recipient's response. The molecular mechanisms underlying the adverse transfusion responses, such as allergic and febrile nonhemolytic reactions, are however, still poorly understood (37).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules

Valkonen

Holopainen

Colas

et al. 2019

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biolog

View full text Add to dashboard Cite

Platelets are collected for transfusion to patients with different hematological disorders, and for logistical reasons, platelets are stored as concentrates. Despite the carefully controlled conditions, platelets become activated during storage, and platelet concentrates (PLCs) may cause adverse inflammatory reactions in the recipients. We studied by mass spectrometry the lipidomic changes during storage of the clinical PLCs, the platelets isolated from PLCs, and the extracellular vesicles (EVs) thereof. The release of EVs from platelets increased with the prolonged storage time. The molar percentages of arachidonic acid-containing species were increased during storage especially in the phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine classes of glycerophopholipids. The increase of these species in the membrane glycerophopholipid composition paralleled the production of both proinflammatory and proresolving lipid mediators (LMs) as the amount of the arachidonic acid-derived LMs such as thromboxane B 2 and prostaglandin E 2 also increased in time. Moreover, several monohydroxy pathway markers and functionally relevant proinflammatory and proresolving LMs were detected in the PLC and the EVs, and some of these clearly accumulated during storage. By Western blot, the key enzymes of these pathways were shown to be present in the platelets and in many cases also in the EVs. Since the EVs were enriched in the fatty acid precursors of LMs, harbored LM-producing enzymes, contained the related monohydroxy pathway markers, and also secreted the final LM products, the

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules

Valkonen

Holopainen

Colas

et al. 2019

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biolog

View full text Add to dashboard Cite

show abstract

“…Soluble GPV was found to increase during the storage in different additive solutions and in plasma, and it was correlated to CD62P, hypotonic shock response (HSR), and lactate concentration. 28 It was proposed as an ex vivo activation marker.…”

Section: Phenotype Of Stored Plateletsmentioning

confidence: 99%

What about Platelet Function in Platelet Concentrates?

Prudent

2020

Hamostaseologie

View full text Add to dashboard Cite

The characterization of platelet concentrates (PCs) in transfusion medicine has been performed with different analytical methods and platelet lesions (from biochemistry to cell biology) have been documented. In routine quality assessment and validation of manufacturing processes of PCs for transfusion purposes, only basic parameters are monitored and the platelet functions are not included. However, PCs undergo several manipulations during the processing and the basic parameters do not provide sensitive analyses to properly picture out the impact of the blood component preparation and storage on platelets. To improve the transfusion supply chain and the platelet functionalities, additional parameters should be used. The present short review will focus on the different techniques to monitor ex vivo platelet lesions from phenotype characterization to advanced omic analyses. Then, the opportunities to use these methods in quality control, process validation, development, and research will be discussed. Functional markers should be considered because they would be an advantage for the future developments in transfusion medicine.

show abstract

“…42,43 Soluble glycoprotein V as a platelet in vitro activation marker was statistically significantly correlated with CD62P. 44 The plasma platelet-derived microparticles level may be a useful indicator of the severity of psoriasis. 45 Moreover, the increased platelet activation might be the missing link between persistent inflammation and development of atherosclerotic plaque leading to cardiovascular co-morbidities seen with psoriasis.…”

Section: Discussionmentioning

confidence: 99%

iTRAQ‐based quantitative proteomics reveals biomarkers/pathways in psoriasis that can predict the efficacy of methotrexate

Yan

Meng

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Methotrexate (MTX) is the first‐line medicine to treat psoriasis. So far, there has been less research on protein biomarkers to predict its efficacy by the proteomic technique. Objectives To evaluate differentially expressed proteins in peripheral mononuclear cells (PBMCs) between good responders (GRs) and non‐responders (NRs) after MTX treatment, compared with normal controls (NCs). Methods We quantified protein expression of PBMCs with four GRs and four NRs to MTX and four NCs by isobaric tags for relative and absolute quantification (iTRAQ), analysing and identifying proteins related to efficacy of MTX in 18 psoriatic patients. Results A total of 3177 proteins had quantitative information, and 403 differentially expressed proteins (fold change ≥1.2, P < 0.05) were identified. Compared to NCs, upregulated proteins (ANXA6, RPS27A, EZR, XRCC6), participating in the activation of NF‐κB, the JAK–STAT pathway and neutrophil degranulation were detected in GRs. The proteins (GPV, FN1, STOM), involving platelet activation, signalling and aggregation as well as neutrophil degranulation were significantly downregulated in GRs. These proteins returned to normal levels after MTX treatment. Furthermore, Western blotting identified the expression of ANXA6 and STAT1 in PBMCs, which were significantly downregulated in GRs, but not in NRs. Conclusions We identified seven differentially expressed and regulated proteins (ANXA6, GPV, FN1, XRCC6, STOM, RPS27A and EZR) as biomarkers to predict MTX efficacy in NF‐κB signalling, JAK–STAT pathways, neutrophil degranulation, platelet activation, signalling and aggregation.

show abstract

Evaluation of soluble glycoprotein V as an in vitro quality marker for platelet concentrates: a correlation study between in vitro platelet quality markers and the effect of storage medium

Cited by 7 publications

References 28 publications

Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules

Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules

What about Platelet Function in Platelet Concentrates?

iTRAQ‐based quantitative proteomics reveals biomarkers/pathways in psoriasis that can predict the efficacy of methotrexate

Contact Info

Product

Resources

About